nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxaprozin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Oxaprozin—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Oxaprozin—Renal failure—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Oxaprozin—Nausea—Mechlorethamine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Oxaprozin—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Oxaprozin—Alopecia—Bleomycin—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Oxaprozin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Oxaprozin—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Oxaprozin—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Oxaprozin—Haemoglobin—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Oxaprozin—Urticaria—Teniposide—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Oxaprozin—Glossitis—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Oxaprozin—Oliguria—Methotrexate—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Oxaprozin—Haemorrhage—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Oxaprozin—Abdominal pain—Teniposide—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Oxaprozin—Body temperature increased—Teniposide—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Oxaprozin—Paraesthesia—Fludarabine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Oxaprozin—Hallucination—Carmustine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Oxaprozin—Dyspnoea—Fludarabine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Oxaprozin—Haematuria—Mitoxantrone—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Oxaprozin—Dyspepsia—Fludarabine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Oxaprozin—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Oxaprozin—Ulcer—Methotrexate—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Oxaprozin—Sinusitis—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Oxaprozin—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Oxaprozin—Decreased appetite—Fludarabine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Oxaprozin—Hallucination—Vincristine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Oxaprozin—Constipation—Fludarabine—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Oxaprozin—Vasculitis—Methotrexate—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Oxaprozin—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Oxaprozin—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Oxaprozin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Oxaprozin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Oxaprozin—Anaemia—Bleomycin—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Oxaprozin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Oxaprozin—Asthenia—Teniposide—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Oxaprozin—Melaena—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Oxaprozin—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Oxaprozin—Malaise—Bleomycin—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Oxaprozin—Pruritus—Teniposide—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Oxaprozin—Arrhythmia—Carmustine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Oxaprozin—Leukopenia—Bleomycin—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Oxaprozin—Cystitis—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Oxaprozin—Alopecia—Carmustine—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Oxaprozin—Body temperature increased—Fludarabine—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Oxaprozin—Aplastic anaemia—Methotrexate—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Oxaprozin—Diarrhoea—Teniposide—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Oxaprozin—Alopecia—Vincristine—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Oxaprozin—Coma—Methotrexate—lymphatic system cancer	0.00208	0.00208	CcSEcCtD
Oxaprozin—Discomfort—Bleomycin—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Oxaprozin—Urine output increased—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Oxaprozin—Ecchymosis—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Oxaprozin—Bladder pain—Methotrexate—lymphatic system cancer	0.00206	0.00206	CcSEcCtD
Oxaprozin—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Oxaprozin—Alopecia—Mitoxantrone—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Oxaprozin—Confusional state—Bleomycin—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Oxaprozin—Vision blurred—Carmustine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Oxaprozin—Tremor—Carmustine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Oxaprozin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Oxaprozin—Oedema—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Oxaprozin—Infection—Bleomycin—lymphatic system cancer	0.002	0.002	CcSEcCtD
Oxaprozin—Anaemia—Carmustine—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Oxaprozin—Vomiting—Teniposide—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Oxaprozin—Sepsis—Methotrexate—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Oxaprozin—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Oxaprozin—Asthenia—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Oxaprozin—Rash—Teniposide—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Oxaprozin—Dermatitis—Teniposide—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Oxaprozin—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Oxaprozin—Headache—Teniposide—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Oxaprozin—Pruritus—Fludarabine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Oxaprozin—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Oxaprozin—Leukopenia—Carmustine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Oxaprozin—Anorexia—Bleomycin—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Oxaprozin—Anaemia—Vincristine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Oxaprozin—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Oxaprozin—Polyuria—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Oxaprozin—Photosensitivity—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Oxaprozin—Hypotension—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Oxaprozin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Oxaprozin—Convulsion—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Oxaprozin—Hypertension—Carmustine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Oxaprozin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Oxaprozin—Nausea—Teniposide—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Oxaprozin—Anaemia—Mitoxantrone—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Oxaprozin—Vertigo—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Oxaprozin—Hepatic failure—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Oxaprozin—Leukopenia—Vincristine—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Oxaprozin—Anxiety—Carmustine—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Oxaprozin—Paraesthesia—Bleomycin—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Oxaprozin—Malaise—Mitoxantrone—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Oxaprozin—Dyspnoea—Bleomycin—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Oxaprozin—Renal failure acute—Methotrexate—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Oxaprozin—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Oxaprozin—Convulsion—Vincristine—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Oxaprozin—Hypertension—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Oxaprozin—Confusional state—Carmustine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Oxaprozin—Oedema—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Oxaprozin—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Oxaprozin—Decreased appetite—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Oxaprozin—Infection—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Oxaprozin—Vomiting—Fludarabine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Oxaprozin—Convulsion—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Oxaprozin—Rash—Fludarabine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Oxaprozin—Dermatitis—Fludarabine—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Oxaprozin—Hypertension—Mitoxantrone—lymphatic system cancer	0.00173	0.00173	CcSEcCtD
Oxaprozin—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Oxaprozin—Headache—Fludarabine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Oxaprozin—Tachycardia—Carmustine—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Oxaprozin—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Oxaprozin—Anxiety—Mitoxantrone—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Oxaprozin—Lethargy—Methotrexate—lymphatic system cancer	0.00169	0.00169	CcSEcCtD
Oxaprozin—Discomfort—Mitoxantrone—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Oxaprozin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Oxaprozin—Oedema—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Oxaprozin—Anorexia—Carmustine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Oxaprozin—Infection—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Oxaprozin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Oxaprozin—Confusional state—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Oxaprozin—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Oxaprozin—Hypotension—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Oxaprozin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Oxaprozin—Oedema—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Oxaprozin—Nausea—Fludarabine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Oxaprozin—Infection—Mitoxantrone—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Oxaprozin—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Oxaprozin—Shock—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Oxaprozin—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Oxaprozin—Urticaria—Bleomycin—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Oxaprozin—Anorexia—Vincristine—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Oxaprozin—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Oxaprozin—Body temperature increased—Bleomycin—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Oxaprozin—Insomnia—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Oxaprozin—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Oxaprozin—Paraesthesia—Carmustine—lymphatic system cancer	0.00158	0.00158	CcSEcCtD
Oxaprozin—Hypotension—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Oxaprozin—Dyspnoea—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Oxaprozin—Somnolence—Carmustine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Oxaprozin—Anorexia—Mitoxantrone—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Oxaprozin—Decreased appetite—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Oxaprozin—Hypotension—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Oxaprozin—Insomnia—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Oxaprozin—Paraesthesia—Vincristine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Oxaprozin—Constipation—Carmustine—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Oxaprozin—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Oxaprozin—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Oxaprozin—Decreased appetite—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Oxaprozin—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Oxaprozin—Somnolence—Mitoxantrone—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Oxaprozin—Feeling abnormal—Carmustine—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Oxaprozin—Asthenia—Bleomycin—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Oxaprozin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Oxaprozin—Constipation—Vincristine—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Oxaprozin—Asthma—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Oxaprozin—Pruritus—Bleomycin—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Oxaprozin—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Oxaprozin—Eosinophilia—Methotrexate—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Oxaprozin—Pancreatitis—Methotrexate—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Oxaprozin—Constipation—Mitoxantrone—lymphatic system cancer	0.0014	0.0014	CcSEcCtD
Oxaprozin—Abdominal pain—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Oxaprozin—Body temperature increased—Carmustine—lymphatic system cancer	0.00139	0.00139	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Oxaprozin—Pancytopenia—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Oxaprozin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Oxaprozin—Dysuria—Methotrexate—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Oxaprozin—Body temperature increased—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Oxaprozin—Abdominal pain—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Oxaprozin—Urticaria—Mitoxantrone—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Oxaprozin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Oxaprozin—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Oxaprozin—Pneumonia—Methotrexate—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Oxaprozin—Vomiting—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Oxaprozin—Drowsiness—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Oxaprozin—Rash—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Oxaprozin—Dermatitis—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Oxaprozin—Asthenia—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Oxaprozin—Renal failure—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Oxaprozin—Stomatitis—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Oxaprozin—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Oxaprozin—Haematuria—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Oxaprozin—Asthenia—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Oxaprozin—Diarrhoea—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Oxaprozin—Nausea—Bleomycin—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Oxaprozin—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Oxaprozin—Asthenia—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Oxaprozin—Dizziness—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Oxaprozin—Haemoglobin—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Oxaprozin—Diarrhoea—Vincristine—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Oxaprozin—Haemorrhage—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Oxaprozin—Hepatitis—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Oxaprozin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Oxaprozin—Vomiting—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Oxaprozin—Dizziness—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Oxaprozin—Rash—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Oxaprozin—Dermatitis—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Oxaprozin—Headache—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Oxaprozin—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Oxaprozin—Tinnitus—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Oxaprozin—Vomiting—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Oxaprozin—Rash—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Oxaprozin—Dermatitis—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Oxaprozin—Headache—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Oxaprozin—Nausea—Carmustine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Oxaprozin—Vomiting—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Oxaprozin—Rash—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Oxaprozin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Oxaprozin—Headache—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Oxaprozin—Alopecia—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Oxaprozin—Nausea—Vincristine—lymphatic system cancer	0.000995	0.000995	CcSEcCtD
Oxaprozin—Dysgeusia—Methotrexate—lymphatic system cancer	0.000975	0.000975	CcSEcCtD
Oxaprozin—Nausea—Mitoxantrone—lymphatic system cancer	0.000969	0.000969	CcSEcCtD
Oxaprozin—Vision blurred—Methotrexate—lymphatic system cancer	0.000939	0.000939	CcSEcCtD
Oxaprozin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000924	0.000924	CcSEcCtD
Oxaprozin—Anaemia—Methotrexate—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Oxaprozin—Malaise—Methotrexate—lymphatic system cancer	0.000898	0.000898	CcSEcCtD
Oxaprozin—Vertigo—Methotrexate—lymphatic system cancer	0.000895	0.000895	CcSEcCtD
Oxaprozin—Leukopenia—Methotrexate—lymphatic system cancer	0.000891	0.000891	CcSEcCtD
Oxaprozin—Convulsion—Methotrexate—lymphatic system cancer	0.000863	0.000863	CcSEcCtD
Oxaprozin—Discomfort—Methotrexate—lymphatic system cancer	0.000838	0.000838	CcSEcCtD
Oxaprozin—Confusional state—Methotrexate—lymphatic system cancer	0.00082	0.00082	CcSEcCtD
Oxaprozin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000813	0.000813	CcSEcCtD
Oxaprozin—Infection—Methotrexate—lymphatic system cancer	0.000807	0.000807	CcSEcCtD
Oxaprozin—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000796	0.000796	CcSEcCtD
Oxaprozin—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000786	0.000786	CcSEcCtD
Oxaprozin—Anorexia—Methotrexate—lymphatic system cancer	0.000775	0.000775	CcSEcCtD
Oxaprozin—Hypotension—Methotrexate—lymphatic system cancer	0.000759	0.000759	CcSEcCtD
Oxaprozin—Insomnia—Methotrexate—lymphatic system cancer	0.000735	0.000735	CcSEcCtD
Oxaprozin—Paraesthesia—Methotrexate—lymphatic system cancer	0.00073	0.00073	CcSEcCtD
Oxaprozin—Dyspnoea—Methotrexate—lymphatic system cancer	0.000725	0.000725	CcSEcCtD
Oxaprozin—Somnolence—Methotrexate—lymphatic system cancer	0.000723	0.000723	CcSEcCtD
Oxaprozin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000715	0.000715	CcSEcCtD
Oxaprozin—Decreased appetite—Methotrexate—lymphatic system cancer	0.000707	0.000707	CcSEcCtD
Oxaprozin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00067	0.00067	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Oxaprozin—Urticaria—Methotrexate—lymphatic system cancer	0.000646	0.000646	CcSEcCtD
Oxaprozin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Oxaprozin—Body temperature increased—Methotrexate—lymphatic system cancer	0.000643	0.000643	CcSEcCtD
Oxaprozin—Asthenia—Methotrexate—lymphatic system cancer	0.000583	0.000583	CcSEcCtD
Oxaprozin—Pruritus—Methotrexate—lymphatic system cancer	0.000575	0.000575	CcSEcCtD
Oxaprozin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000556	0.000556	CcSEcCtD
Oxaprozin—Dizziness—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Oxaprozin—Vomiting—Methotrexate—lymphatic system cancer	0.000517	0.000517	CcSEcCtD
Oxaprozin—Rash—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Oxaprozin—Dermatitis—Methotrexate—lymphatic system cancer	0.000512	0.000512	CcSEcCtD
Oxaprozin—Headache—Methotrexate—lymphatic system cancer	0.000509	0.000509	CcSEcCtD
Oxaprozin—Nausea—Methotrexate—lymphatic system cancer	0.000483	0.000483	CcSEcCtD
